Aminoglycoside use in cystic fibrosis: Therapeutic strategies and toxicity

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 6, 2010, Pages 604-610

  Prayle, Andrew ^a   Smyth, Alan R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aminoglycosides; cystic fibrosis; hearing loss; kidney disease; toxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GALLIUM; GENTAMICIN; TOBRAMYCIN;

CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG INDICATION; DRUG USE; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LUNG INFECTION; NEPHROTOXICITY; OTOTOXICITY; PSEUDOMONAS INFECTION; REVIEW; VESTIBULAR DISORDER;

ACUTE KIDNEY INJURY; AMINOGLYCOSIDES; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENTAMICINS; HUMANS; TOBRAMYCIN;

EID: 77958154266     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833eebfd     Document Type: Review

References (48)

1. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139:359-365. (Pubitemid 32889511)
2. Smyth A, Tan KHV, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis: the TOPIC study -a randomised controlled trial. Lancet 2005; 365:573-578. (Pubitemid 40247913)
3. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2010: CD002009. doi: 10.1002/14651858.CD002009.pub3.
4. Riethmueller J, Ballmann M, Schroeter TW, et al. Tobramycin once-vs thricedaily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009; 37:424-431.
5. Elphick HE, Tan AA. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005:CD002007. doi: 10.1002/14651858.CD002007.pub2.
6. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180:802-808.
7. UK CF Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis. Cystic Fibrosis Trust; 2009.
8. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16:749-767. (Pubitemid 32223852)
9. Soulsby N, Bell S, Greville H, et al. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new? Intern Med J 2009; 39:527-531.
10. Van Meter DJ, Corriveau M, Ahern JW, et al. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44:325-329.
11. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42:601-605. (Pubitemid 44341888)
12. Coulthard KP, Peckham DG, Conway SP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis: caution with trough concentrations. J Cyst Fibros 2007; 6:125-130.
13. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003:CD001021. doi: 10.1002/14651858.CD001021.
14. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-664.
15. Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008; 43:874-881.
16. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis: control and treatment of infection. J Cyst Fibros 2009; 8:211-217.
17. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61:859-868. (Pubitemid 351426071)
18. Halwani M, Yebio B, Suntres ZE, et al. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 2008; 62:1291-1297.
19. Alipour M, Suntres ZE, Halwani M, et al. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One 2009; 4:e5724.
20. Dupont L, Minic P, Fustic S, et al. A randomized placebo-controlled study of nebulized liposomal amikacin [Arikace(TM)] in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros 2008; 7:S26-S126.
21. Parlati C, Colombo P, Buttini F, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res 2009; 26:1084-1092.
22. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286-291.
23. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early antipseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009; 30:256-268.
24. Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813-821. (Pubitemid 351358357)
25. Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45:363-370.
26. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44:547-558.
27. Schurek KN, Marr AK, Taylor PK, et al. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52:4213-4219.
28. Moriarty TF, McElnay JC, Elborn JS, et al. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007; 42:1008-1017.
29. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008:CD006961. (Pubitemid 351807500)
30. Foweraker JE, Laughton CR, Brown DF, et al. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother 2009; 53:4809-4815.
31. Smyth A, Lewis S, Bertenshaw C, et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63:532-535 (Pubitemid 351831165)
32. Al-AloulM, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15-20. (Pubitemid 39628598)
33. Eckardt KU, Berns JS, Rocco MV, et al. Definition and classification of CKD: the debate should be about patient prognosis -a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53:915-920.
34. Beringer PM, Hidayat L, Heed A, et al. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros 2009; 8:19-25.
35. Al-Aloul M, Jackson M, Bell G, et al. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros 2007; 6:41-47. (Pubitemid 46039452)
36. Soulsby N, Greville H, Coulthard K, et al. What is the best method for measuring renal function in adults and children with cystic fibrosis? J Cyst Fibros 2010; 9:124-129.
37. Hmiel SP, Beck AM, de la Morena MT, et al. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 2005; 5:1739-1747. (Pubitemid 40910458)
38. Hornum M, Iversen M, Steffensen I, et al. Rapid decline in 51Cr-EDTA measured renal function during the first weeks following lung transplantation. Am J Transplant 2009; 9:1420-1426.
39. Watson AR. Aminoglycosides, toxicity and cystic fibrosis. J R Soc Med 2007; 100 (Suppl 47):24-28.
40. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007; 6:327-333. (Pubitemid 47324148)
41. Mulheran M, Degg C, Burr S, et al. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 2001; 45:2502-2509. (Pubitemid 32801902)
42. Mulheran M, Hyman-Taylor P, Tan KH, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once-versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50:2293-2299. (Pubitemid 43993165)
43. Scheenstra RJ, Heijerman HG, Zuur CL, et al. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Otolaryngol 2010; 130:253-258.
44. Martins LM, Camargos PA, Becker HM, et al. Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol 2010; 74:469-473.
45. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A!G mutation in European children. N Engl J Med 2009; 360:640-642.
46. Conrad DJ, Stenbit AE, Zettner EM, et al. Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics 2008; 18:1095-1102.
47. Veenstra DL, Harris J, Gibson RL, et al. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 2007; 9:695-704. (Pubitemid 350287155)
48. Scheenstra RJ, Rijntjes E, Tavy DL, et al. Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients. Acta Otolaryngol 2009; 129:4-7.